| ID | 118447 |
| タイトル別表記 | High-absorption curcumin reduces BNP in hypertensive heart disease
|
| 著者 |
船本, 雅文
National Hospital Organization Kyoto Medical Center|University of Shizuoka|Tokushima University
徳島大学 教育研究者総覧
KAKEN研究者をさがす
Sunagawa, Yoichi
National Hospital Organization Kyoto Medical Center|University of Shizuoka
Katanasaka, Yasufumi
National Hospital Organization Kyoto Medical Center|University of Shizuoka
Kato, Toru
National Hospital Organization Tochigi Medical Center
Funada, Junichi
National Hospital Organization Ehime Medical Center
Ajiro, Yoichi
National Hospital Organization Yokohama Medical Center
Komiyama, Maki
National Hospital Organization Kyoto Medical Center
Akao, Masaharu
National Hospital Organization Kyoto Medical Center
Yasoda, Akihiro
National Hospital Organization Kyoto Medical Center
Yamakage, Hajime
National Hospital Organization Kyoto Medical Center
Satoh-Asahara, Noriko
National Hospital Organization Kyoto Medical Center
Wada, Hiromichi
National Hospital Organization Kyoto Medical Center
Morimoto, Tatsuya
National Hospital Organization Kyoto Medical Center|University of Shizuoka
Hasegawa, Koji
National Hospital Organization Kyoto Medical Center|University of Shizuoka
|
| キーワード | Curcumin
Hypertension
Cardiac hypertrophy
Diastolic dysfunction
B-type natriuretic peptide
Prevention
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | Aims
Hypertension is a strong risk factor for heart failure with preserved ejection fraction. Curcumin has p300-specific histone acetyltransferase inhibitory activity, suppresses cardiomyocyte hypertrophy and fibrosis, and significantly reduces myocardial brain natriuretic peptide (BNP) expression without altering blood pressure in a rat model of hypertensive heart disease. This double-blind, placebo-controlled, randomized study, for the first time, aimed to examine the efficacy of a high-absorption curcumin for the prevention of hypertensive heart disease in humans. Methods and results Patients exhibiting initial signs of hypertensive heart disease with left ventricular ejection fraction ≥60% and stable blood pressure <140/90 mmHg orally took a double-blinded capsule (either a 90 mg curcumin capsule or placebo) twice daily for 24 weeks. The primary endpoint was per cent changes in left ventricular diastolic function (E/E′) from baseline to 6 months after administration. The secondary endpoint was the per cent change in plasma BNP levels. The E/E′ ratio per cent change from baseline to 6 months after administration was similar between the placebo (n = 69) and the curcumin (n = 73) groups. The per cent change in plasma BNP levels was significantly lower in the curcumin group than in the placebo group. In patients <65 years, BNP per cent changes were significantly lower in the curcumin group than in the placebo group, but similar between groups in ≥65 years (<65 vs. ≥65 years: P for interaction = 0.011). Conclusions A high-absorption curcumin agent did not affect the E/E′ ratio, rather it significantly inhibited the increase in plasma BNP levels in patients with initial signs of hypertensive heart disease. |
| 掲載誌名 |
European Heart Journal Open
|
| ISSN | 27524191
|
| 出版者 | Oxford University Press|European Society of Cardiology
|
| 巻 | 2
|
| 号 | 5
|
| 開始ページ | oeac057
|
| 発行日 | 2022-09-10
|
| 権利情報 | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
|
| EDB ID | |
| 出版社版DOI | |
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
